Recent Updates
Recently added Catalysts

BL 1020

Phase 1

Healthy | Small molecule | Other |BioLineRx Ltd.|Last Updated: Jul 21, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00480246A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET TracerPHASE1 COMPLETED -May 1, 2007 -Jul 21, 20091 Sweden
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
Interventions
NameTypeDescription
BL 1020DRUG -
PerphenazineDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 35 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Voluntarily signed written informed consent agreement approved by the Independent Ethics Committee (IEC) after explanation of the nature and objectives of the study and prior to any study specific procedure. 2. Healthy male subjects between the age of 21 and 35 (inclusive). 3...

Countries:Sweden
Unlock Eligibility Criteria